Illumina Inc   (ILMN)
Other Ticker:  
Price: $139.7600 $2.79 2.037%
Day's High: $140.05 Week Perf: 2.46 %
Day's Low: $ 134.79 30 Day Perf: -0.62 %
Volume (M): 1,323 52 Wk High: $ 238.55
Volume (M$): $ 184,875 52 Wk Avg: $165.77
Open: $137.03 52 Wk Low: $89.00

 Market Capitalization (Millions $) 22,106
 Shares Outstanding (Millions) 158
 Employees 9,800
 Revenues (TTM) (Millions $) 4,504
 Net Income (TTM) (Millions $) -1,161
 Cash Flow (TTM) (Millions $) -963
 Capital Exp. (TTM) (Millions $) 196

Illumina Inc
Illumina Inc.
is an American company that specializes in the production of genetic analysis tools, including next-generation sequencing (NGS) instruments, software, and consumables.
The company was founded in 1998 and is headquartered in San Diego, California.
The company's flagship product is the Genome Analyzer, which is used for high-throughput DNA sequencing.
Illumina's sequencing systems use proprietary chemistry and software to produce highly accurate and reliable data, enabling researchers to study genetic variation and disease pathways.
Illumina's products and services are used in various fields such as healthcare, research, and agriculture, to analyze and decode genetic information.
The company has partnerships with major pharmaceutical and biotechnology companies, as well as academic and research institutions, to develop new therapies and treatments for diseases like cancer, diabetes, and rare genetic disorders.
In addition to its sequencing instruments, Illumina offers a range of other analysis tools, including microarrays, PCR (polymerase chain reaction) kits, and software platforms.
The company's services include sequencing and data analysis for both research use and clinical diagnostics.
Illumina has a strong focus on innovation, reflected in its ongoing efforts to improve its technology and offer new tools and solutions.
The company has also been involved in several high-profile scientific initiatives, including the 100,000 Genomes Project in the UK and the All of Us Research Program in the US.
Overall, Illumina Inc is a leading player in the field of genetic analysis, providing cutting-edge technology and services to facilitate research and advance science.

   Company Address: 5200 Illumina Way San Diego 92122 CA
   Company Phone Number: 202-4500   Stock Exchange / Ticker: NASDAQ ILMN


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Illumina Inc

Illumina Inc Reports Modest 3.506% Revenue Increase in Q4 20232.

Illumina Inc, a leading company in the Laboratory Analytical Instruments sector, has recently reported its fiscal results for the three months ending December 31, 2023. Despite a net loss per share of $-1.11, which was higher than the previous year's $-0.87, the company saw a 3.506% increase in revenue to $1.12 billion compared to the same period a year ago.
Many analysts were surprised by Illumina Inc's revenue gain, especially considering the overall contraction of 11.60% in the Laboratory Analytical Instruments sector. In the previous financial reporting period, the company had achieved revenue of $1.12 billion and a bottom line of $-4.77 per share.

Illumina Inc

Illumina Inc. Demonstrates Steady Growth with a Reasonable Performance in Fiscal Third Quarter of 2023

Illumina Inc, a Laboratory Analytical Instruments company, experienced a challenging third quarter in 2023, reporting a loss of $-4.77 per share. This marked an improvement from the previous year, where the loss per share was significantly higher at $-24.26.
Interestingly, while most companies in the Laboratory Analytical Instruments sector saw a decline in revenue, Illumina Inc managed to achieve a slight growth of 0.359%. The company's revenue reached $1.12 billion during the quarter, compared to $1.12 billion in the same period the previous year. However, there was a sequential decrease in revenue of -4.847% from $1.18 billion.

Illumina Inc

Illumina Inc. Breaks Records with $81 Million Tax Bonus, Boosting Earnings to New Heights.

Illumina Inc. (ILMN), a pioneer in the field of genomics research and technology, recently announced its financial results for the first quarter of 2023. Despite a slight decline in revenue, the company was able to turn a profit, marking a significant improvement over the same period in 2022.
In the first quarter of 2023, ILMN reported earnings per share (EPS) of $0.02, a significant increase from the EPS of -$0.87 reported in the prior year. The company's revenue in Q1 2023 was $1.09 billion, a decrease of -2.511% from the same period last year. However, the revenue still showed an overall increase of 0.277% from the prior reporting period, indicating that the company is on a gradual path of growth.


Illumina Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Illumina Inc does not provide revenue guidance.

Earnings Outlook
Illumina Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com